Connection

Contact Us
If you have any questions or feedback please contact us.

Search Results to Peter Ashley Gottlieb

This is a "connection" page, showing the details of why an item matched the keywords from your search.

Search Results

Gottlieb, Peter

One or more keywords matched the following items that are connected to Gottlieb, Peter

Item Type	Name
Academic Article	Dual overlapping peptides recognized by insulin peptide B:9-23 T cell receptor AV13S3 T cell clones of the NOD mouse.
Academic Article	Insulin-specific tolerance in diabetes.
Academic Article	HLA-DQ8-associated T cell responses to the diabetes autoantigen phogrin (IA-2 beta) in human prediabetes.
Academic Article	T cells recognize multiple GAD65 and proinsulin epitopes in human type 1 diabetes, suggesting determinant spreading.
Academic Article	Immunomodulation in type 1 diabetes by NBI-6024, an altered peptide ligand of the insulin B epitope.
Academic Article	Recognition of HLA class I-restricted beta-cell epitopes in type 1 diabetes.
Academic Article	Rituximab, B-lymphocyte depletion, and preservation of beta-cell function.
Academic Article	Sample size requirements for studies of treatment effects on beta-cell function in newly diagnosed type 1 diabetes.
Academic Article	Teplizumab treatment may improve C-peptide responses in participants with type 1 diabetes after the new-onset period: a randomised controlled trial.
Academic Article	Immune therapy and ?-cell death in type 1 diabetes.
Academic Article	T cell receptor restriction of diabetogenic autoimmune NOD T cells.
Academic Article	A disease-associated cellular immune response in type 1 diabetics to an immunodominant epitope of insulin.
Academic Article	Immunological characterization and therapeutic activity of an altered-peptide ligand, NBI-6024, based on the immunodominant type 1 diabetes autoantigen insulin B-chain (9-23) peptide.
Academic Article	Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb Teplizumab preserves insulin production for up to 5 years.
Academic Article	Fall in C-peptide during first 2 years from diagnosis: evidence of at least two distinct phases from composite Type 1 Diabetes TrialNet data.
Academic Article	Structure-based selection of small molecules to alter allele-specific MHC class II antigen presentation.
Academic Article	Plasmid-encoded proinsulin preserves C-peptide while specifically reducing proinsulin-specific CD8? T cells in type 1 diabetes.
Concept	C-Peptide
Concept	Peptide Fragments
Academic Article	Clinical optimization of antigen specific modulation of type 1 diabetes with the plasmid DNA platform.
Academic Article	Teplizumab (anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial: metabolic and immunologic features at baseline identify a subgroup of responders.
Academic Article	Costimulation modulation with abatacept in patients with recent-onset type 1 diabetes: follow-up 1 year after cessation of treatment.
Academic Article	Reduction in CD4 central memory T-cell subset in costimulation modulator abatacept-treated patients with recent-onset type 1 diabetes is associated with slower C-peptide decline.
Academic Article	Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes.
Academic Article	Anti-thymocyte globulin/G-CSF treatment preserves ? cell function in patients with established type 1 diabetes.
Academic Article	Alefacept provides sustained clinical and immunological effects in new-onset type 1 diabetes patients.
Academic Article	Antithymocyte globulin therapy for patients with recent-onset type 1 diabetes: 2?year results of a randomised trial.
Academic Article	Do Electrochemiluminescence Assays Improve Prediction of Time to Type 1 Diabetes in Autoantibody-Positive TrialNet Subjects?
Academic Article	Antithymocyte Globulin Plus G-CSF Combination Therapy Leads to Sustained Immunomodulatory and Metabolic Effects in a Subset of Responders With Established Type 1 Diabetes.
Academic Article	Islet-Derived CD4 T Cells Targeting Proinsulin in Human Autoimmune Diabetes.
Grant	IMMUNOTHERAPY TRIAL IN NEW ONSET TYPE 1 DIABETES
Grant	Human TCR/HLA Transgenic Mice to Prevent T1DM
Grant	TrialNet: Diabetes Type 1 Prevention
Academic Article	Low-Dose Anti-Thymocyte Globulin (ATG) Preserves ?-Cell Function and Improves HbA1c in New-Onset Type 1 Diabetes.
Academic Article	Treatment of type 1 diabetes with teplizumab: clinical and immunological follow-up after 7?years from diagnosis.
Academic Article	Low-Dose Anti-Thymocyte Globulin Preserves C-Peptide, Reduces HbA1c, and Increases Regulatory to Conventional T-Cell Ratios in New-Onset Type 1 Diabetes: Two-Year Clinical Trial Data.
Academic Article	Clinical trial data validate the C-peptide estimate model in type 1 diabetes.
Academic Article	Low-Dose ATG/GCSF in Established Type 1 Diabetes: A Five-Year Follow-up Report.
Academic Article	Proinsulin:C-peptide ratio trajectories over time in relatives at increased risk of progression to type 1 diabetes.
Academic Article	Simplifying prediction of disease progression in pre-symptomatic type 1 diabetes using a single blood sample.
Academic Article	Peptide fragments from the tuftsin containing domain of immunoglobulin G synthesis and biological activity.
Academic Article	Teplizumab: A Disease-Modifying Therapy for Type 1 Diabetes That Preserves ?-Cell Function.
Academic Article	C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis.

Search Criteria

C Peptide